In the subgroup analysis by type of neurodegenerative diseases and galectin, it was shown that patients with AD, PD, and ALS have higher levels of galectin-3 expression, and in the case of patients with MS, higher expression of gal 9 was found. This evidence concerns the gene LGALS3 and Parkinson disease.